Physician profile
Sandeep Gupta
NPI 1194794305
$20,394.16
in general payments reported to CMS, 2019-2025
29 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,492 · 2020: $2,273 · 2021: $2,934 · 2022: $4,016 · 2023: $3,342 · 2024: $2,707 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,590 · Education: $90.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,589.55 |
| Education | $90.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,428.09 | 2019-2025 | |
| Amgen INC. | $3,124.89 | 2019-2025 | Evenity, Enbrel, Krystexxa |
| Glaxosmithkline, LLC. | $1,549.14 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $1,516.11 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $1,270.76 | 2019-2025 | |
| Ucb, INC. | $1,094.50 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $995.97 | 2021-2025 | Saphnelo, Breztri |
| Janssen Biotech, INC. | $951.61 | 2019-2025 | Tremfya, Stelara, Remicade |
| Mallinckrodt Hospital Products INC. | $947.01 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $871.42 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $804.11 | 2019-2025 | Cobenfy, Orencia |
| Ge Healthcare | $764.73 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.69 | 2020-2023 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $585.43 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $372.63 | 2019-2023 | Mitigare |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $370.70 | 2019 | |
| Aurinia Pharma U.S., INC. | $290.61 | 2021-2025 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $213.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $103.80 | 2023-2025 | Strensiq |
| Genzyme Corporation | $92.24 | 2020-2024 | |
| Sobi, INC | $89.97 | 2019-2025 | |
| Depuy Synthes Sales INC. | $80.73 | 2021-2022 | |
| Bioventus LLC | $75.85 | 2019-2024 | Supartz Fx Sodium Hyaluronate |
| Genentech USA, INC. | $47.95 | 2019-2025 | Actemra |
| Scilex Pharmaceuticals INC. | $42.16 | 2024 | |
| Pacira Therapeutics, INC. | $25.59 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.38 | 2024 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $20.80 | 2021 | |
| Organon LLC | $15.95 | 2023 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.